Figure 3

Biodistribution studies of bevacizumab-AlexaFluor 750 in HT29, human colon cancer bearing mice at 15 min, 24 h and 48 h. Data compare in percent injected dose per gram in the organs after injection with bevacizumab-AlexaFluor 750. Tumor uptake reached the peak at 24 h.